PURPOSE: Ovarian carcinoma is the third most common gynecological cancer and only short recurrence-free survival and overall survival times are achieved. The role of the estrogen receptor expression is well studied in breast cancer and breast cancer cell lines. Patients with positive estrogen receptor expression have a lower risk for recurrence and a better overall survival. Previous studies have shown that ESR1 methylation influences ovarian cancer development and might thus play a role regarding prognosis of ovarian carcinoma. METHODS: A total of 75 patients were identified that were treated for ovarian carcinoma by debulking surgery and adjuvant standard chemotherapy. Isolation and bisulfite treatment of genomic DNA from serial sections of surgically resected ovarian carcinoma tissue was performed using commercially available kits. For the detection of methylated ESR1 promoter sequences, real-time methylation-specific PCR was used. RESULTS: Promoter methylation did not show a correlation between clinical-pathological data for all patients. However, within the subgroup of low-grade ovarian carcinoma patients and patients with an ovarian tumor of low malignant potential methylation of the ESR1 promoter inversely correlated with survival (p = 0.031). CONCLUSIONS: Although small numbers of ovarian carcinoma patients were analyzed, methylation status might be useful as a prognostic marker within the subgroup of low-grade ovarian carcinoma patients. Further studies should investigate a larger cohort and also address the use of demethylation agents with respect to improve patient's prognosis in this subgroup of ovarian carcinoma patients.
PURPOSE:Ovarian carcinoma is the third most common gynecological cancer and only short recurrence-free survival and overall survival times are achieved. The role of the estrogen receptor expression is well studied in breast cancer and breast cancer cell lines. Patients with positive estrogen receptor expression have a lower risk for recurrence and a better overall survival. Previous studies have shown that ESR1 methylation influences ovarian cancer development and might thus play a role regarding prognosis of ovarian carcinoma. METHODS: A total of 75 patients were identified that were treated for ovarian carcinoma by debulking surgery and adjuvant standard chemotherapy. Isolation and bisulfite treatment of genomic DNA from serial sections of surgically resected ovarian carcinoma tissue was performed using commercially available kits. For the detection of methylated ESR1 promoter sequences, real-time methylation-specific PCR was used. RESULTS: Promoter methylation did not show a correlation between clinical-pathological data for all patients. However, within the subgroup of low-grade ovarian carcinomapatients and patients with an ovarian tumor of low malignant potential methylation of the ESR1 promoter inversely correlated with survival (p = 0.031). CONCLUSIONS: Although small numbers of ovarian carcinomapatients were analyzed, methylation status might be useful as a prognostic marker within the subgroup of low-grade ovarian carcinomapatients. Further studies should investigate a larger cohort and also address the use of demethylation agents with respect to improve patient's prognosis in this subgroup of ovarian carcinomapatients.
Authors: C A Eads; R V Lord; S K Kurumboor; K Wickramasinghe; M L Skinner; T I Long; J H Peters; T R DeMeester; K D Danenberg; P V Danenberg; P W Laird; K A Skinner Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: J P Issa; B A Zehnbauer; C I Civin; M I Collector; S J Sharkis; N E Davidson; S H Kaufmann; S B Baylin Journal: Cancer Res Date: 1996-03-01 Impact factor: 12.701
Authors: Sahar Houshdaran; Sarah Hawley; Chana Palmer; Mihaela Campan; Mari N Olsen; Aviva P Ventura; Beatrice S Knudsen; Charles W Drescher; Nicole D Urban; Patrick O Brown; Peter W Laird Journal: PLoS One Date: 2010-02-22 Impact factor: 3.240
Authors: P A Newcomb; M P Longnecker; B E Storer; R Mittendorf; J Baron; R W Clapp; G Bogdan; W C Willett Journal: Am J Epidemiol Date: 1995-10-15 Impact factor: 4.897
Authors: R G Lapidus; A T Ferguson; Y L Ottaviano; F F Parl; H S Smith; S A Weitzman; S B Baylin; J P Issa; N E Davidson Journal: Clin Cancer Res Date: 1996-05 Impact factor: 12.531
Authors: Andrew E Teschendorff; Usha Menon; Aleksandra Gentry-Maharaj; Susan J Ramus; Simon A Gayther; Sophia Apostolidou; Allison Jones; Matthias Lechner; Stephan Beck; Ian J Jacobs; Martin Widschwendter Journal: PLoS One Date: 2009-12-18 Impact factor: 3.240
Authors: George S Watts; Bernard W Futscher; Nicholas Holtan; Koen Degeest; Frederick E Domann; Stephen L Rose Journal: BMC Med Genomics Date: 2008-09-30 Impact factor: 3.063